Quantum dots induce charge-specific amyloid-like fibrillation of insulin at physiological conditions

Progress in Biomedical Optics and Imaging - Proceedings of SPIE

Volumn 8548, Issue , 2012, Pages

  Sukhanova, Alyona ^a,b   Poly, Simon ^c   Shemetov, Anton ^b   Nabiev, Igor R ^a,b  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b NATIONAL RESEARCH NUCLEAR UNIVERSITY MEPHI   (Russian Federation)

^c CIC NANOGUNE   (Spain)

Author keywords

amyloidosis; insulin; nanoparticles; proteopathies; quantum dots; secondary structure

Indexed keywords

AMYLOID-LIKE FIBRIL; AMYLOIDOSIS; COMPARATIVE ANALYSIS; NANOPARTICLE (NPS); PHYSIOLOGICAL CONDITION; PROTEIN SECONDARY STRUCTURE; PROTEOPATHIES; SECONDARY STRUCTURES;

DIAGNOSIS; DISEASES; DYNAMIC LIGHT SCATTERING; EMISSION SPECTROSCOPY; GLYCOPROTEINS; INSULIN; NANOPARTICLES; NANOSYSTEMS; PHYSIOLOGY; SEMICONDUCTOR QUANTUM DOTS;

PROTEINS;

EID: 84875727417     PISSN: 16057422     EISSN: None     Source Type: Conference Proceeding    
DOI: 10.1117/12.946606     Document Type: Conference Paper

References (36)

1. Dobson, C.M., "Protein misfolding, evolution and disease," Trends Biochem. Sci. 24, 329-332 (1999).
2. Glabe, C.G., "Common mechanisms of amyloid oligomer pathogenesis in degenerative disease," Neurobiol. Aging 27, 570-575 (2006).
3. Moore, R.A., Hayes, S.F., Fischer, E.R. and Priola, S.A., "Amyloid formation via supramolecular peptide assemblies," Biochemistry 46, 7079-7087 (2007).
4. Go, N., "The consistency principle in protein structure and pathways of folding," Adv. Biophys. 18, 149-64 (1984).
5. Chiti, F. and Dobson, C.M., "Protein misfolding, functional amyloid, and human disease," Annu. Rev. Biochem. 75, 333-366 (2006).
6. Nguyen, J., Baldwin, M.A., Cohen, F.E. and Prusiner, S.B., "Prion protein peptides induce alpha-helix to beta-sheet conformational transitions," Biochemistry 34, 4186-4192 (1995).
7. Abelein, A., Bolognesi, B., Dobson, C.M., Graslund, A. and Lendel, C., "Hydrophobicity and conformational change as mechanistic determinants for nonspecific modulators of amyloid beta self-assembly," Biochemistry 51, 126-137 (2012).
8. Pawar, A.P., Dubay, K.F., Zurdo, J., Chiti, F., Vendruscolo, M. and Dobson, C.M., "Prediction of "aggregationprone" and "aggregation-susceptible" regions in proteins associated with neurodegenerative diseases," J. Mol. Biol. 350, 379-392 (2005).
9. Chiti, F. and Dobson, C.M., "Amyloid formation by globular proteins under native conditions," Nat. Chem. Biol. 5, 15-22 (2009).
10. DeMarco, M.L. and Daggett, V., "From conversion to aggregation: protofibril formation of the prion protein," Proc. Natl. Acad. Sci. USA 101, 2293-2298 (2004).
11. de Groot, N.S., Sabate, R. and Ventura, S., "Amyloids in bacterial inclusion bodies," Trends Biochem. Sci. 34, 408-416 (2009).
12. Pastor, M.T., Esteras-Chopo, A. and Serrano, L., "Hacking the code of amyloid formation: the amyloid stretch hypothesis," Prion 1, 9-14 (2007).
13. Zhang, S., Iwata, K., Lachenmann, M.J., Peng, J.W., Li, S., Stimson, E.R., Lu, Y., Felix, A.M., Maggio, J.E. and Lee, J.P., "The Alzheimer's peptide a beta adopts a collapsed coil structure in water," J. Struct. Biol. 130, 130-141 (2000).
14. Giasson, B.I., Forman, M.S., Higuchi, M., Golbe, L.I., Graves, C.L., Kotzbauer, P.T., Trojanowski, J.Q. and Lee, V.M., "Initiation and synergistic fibrillization of tau and alpha-synuclein," Science 300, 636-640 (2003).
15. Bucciantini, M., Giannoni, E., Chiti, F., Baroni, F., Formigli, L., Zurdo, J., Taddei, N., Ramponi, G., Dobson, C.M. and Stefani, M., "Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases," Nature 416, 507-511 (2002).
16. Jimenez, J.L., Nettleton, E.J., Bouchard, M., Robinson, C.V., Dobson, C.M. and Saibil, H.R., "The protofilament structure of insulin amyloid fibrils," Proc. Natl. Acad. Sci. USA 99, 9196-9201 (2002).
17. Chang, X., Jorgensen, A.M., Bardrum, P. and Led, J.J., "Solution structures of the R6 human insulin hexamer," Biochemistry 36, 9409-9422 (1997).
18. Xu, Y., Yan, Y., Seeman, D., Sun, L. and Dubin, P.L., "Multimerization and aggregation of native-state insulin: effect of zinc," Langmuir 28, 579-86 (2012).
19. Vestergaard, B., Groenning, M., Roessle, M., Kastrup, J.S., van de Weert, M., Flink, J.M., Frokjaer, S., Gajhede, M. and Svergun, D.I., "A helical structural nucleus is the primary elongating unit of insulin amyloid fibrils," PLoS Biol. 5, e134 (2007).
20. Nielsen, L., Frokjaer, S., Carpenter, J.F. and Brange, J., "Studies of the structure of insulin fibrils by Fourier transform infrared (FTIR) spectroscopy and electron microscopy" J. Pharm. Sci. 90, 29-37 (2001).
21. Nielsen, L., Khurana, R., Coats, A., Frokjaer, S., Brange, J., Vyas, S., Uversky, V.N. and Fink, A.L., "Effect of environmental factors on the kinetics of insulin fibril formation: elucidation of the molecular mechanism," Biochemistry 40, 6036-6046 (2001).
22. Pease, L.F., 3rd, Sorci, M., Guha, S., Tsai, D.H., Zachariah, M.R., Tarlov, M.J. and Belfort, G., "Probing the nucleus model for oligomer formation during insulin amyloid fibrillogenesis," Biophys. J. 99, 3979-3985 (2010).
23. Sluzky, V., Tamada, J.A., Klibanov, A.M. and Langer, R., "Kinetics of insulin aggregation in aqueous solutions upon agitation in the presence of hydrophobic surfaces," Proc. Natl. Acad. Sci. USA, 88, 9377-9381 (1991).
24. Georganopoulou, D.G., Chang, L., Nam, J.M., Thaxton, C.S., Mufson, E.J., Klein, W.L. and Mirkin, C.A., "Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease," Proc. Natl. Acad. Sci. USA 102, 2273-2276 (2005).
25. Xiao, L., Zhao, D., Chan, W.H., Choi, M.M. and Li, H.W., "Inhibition of beta 1-40 amyloid fibrillation with Nacetyl-L-cysteine capped quantum dots," Biomaterials 31, 91-98 (2010).
26. Linse, S., Cabaleiro-Lago, C., Xue, W.F., Lynch, I., Lindman, S., Thulin, E., Radford, S.E. and Dawson, K.A., "Nucleation of protein fibrillation by nanoparticles," Proc. Natl. Acad. Sci. USA 104, 8691-8696 (2007).
27. Skaat, H., Sorci, M., Belfort, G. and Margel, S., "Effect of maghemite nanoparticles on insulin amyloid fibril formation: selective labeling, kinetics, and fibril removal by a magnetic field," J. Biomed. Mater. Res. A 91, 342-351 (2009).
28. Yu, W.W., Chang, E., Drezek, R. and Colvin, V.L., "Water-soluble quantum dots for biomedical applications," Biochem. Biophys. Res. Commun. 348, 781-786 (2006).
29. Medintz, I.L., Uyeda, H.T., Goldman, E.R. and Mattoussi, H., "Quantum dot bioconjugates for imaging, labelling and sensing," Nat. Mater. 4, 435-446 (2005).
30. Shemetov, A.A., Nabiev, I. and Sukhanova, A., "Molecular interaction of proteins and peptides with nanoparticles," ACS Nano 6, 4585-4602 (2012).
31. Yoo, S.I., Yang, M., Brender, J.R., Subramanian, V., Sun, K., Joo, N.E., Jeong, S.H., Ramamoorthy, A. and Kotov, N.A., "Inhibition of amyloid peptide fibrillation by inorganic nanoparticles: functional similarities with proteins," Angew. Chem. Int. Ed. 50, 5110-5115 (2011).
32. Thakur, G., Micic, M., Yang, Y., Li, W., Movia, D., Giordani, S., Zhang, H. and Leblanc, R.M., "Conjugated quantum dots inhibit the amyloid beta (1-42) fibrillation process," Int. J. Alzheimers Dis. 2011, 502386 (2011).
33. Bouchard, M., Zurdo, J., Nettleton, E.J., Dobson, C.M. and Robinson, C.V., "Formation of insulin amyloid fibrils followed by FTIR simultaneously with CD and electron microscopy," Protein Sci. 9, 1960-1967 (2000).
34. LeVine, H., 3rd, "Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution," Protein Sci. 2, 404-410 (1993).
35. Wagner, S.C., Roskamp, M., Pallerla, M., Araghi, R.R., Schlecht, S. and Koksch, B., "Nanoparticle-induced folding and fibril formation of coiled-coil-based model peptides," Small 6, 1321-1328 (2010).
36. Wu, W.H., Sun, X., Yu, Y.P., Hu, J., Zhao, L., Liu, Q., Zhao, Y.F. and Li, Y.M., "TiO2 nanoparticles promote betaamyloid fibrillation in vitro," Biochem. Biophys. Res. Commun. 373, 315-318 (2008).